Enhancement of Cytotoxicity by the Combination of Anticancer Drugs in Human Lung Adenocarcinoma Cell Line (PC-14).
10.4046/trd.1997.44.3.525
- Author:
Choon Taek LEE
- Publication Type:In Vitro ; Original Article
- Keywords:
Lung cancer;
Combination chemotherapy;
MTT assay;
Cytotoxicity
- MeSH:
Adenocarcinoma*;
Carcinoma, Non-Small-Cell Lung;
Cell Line*;
Cisplatin;
Doxorubicin;
Drug Combinations;
Drug Therapy;
Drug Therapy, Combination;
Etoposide;
Humans*;
Lung Neoplasms;
Lung*;
Mitomycin
- From:Tuberculosis and Respiratory Diseases
1997;44(3):525-533
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: No ideal combination chemotherapy for lung cancer has been established even though lots of combination anticancer chemotherapies have been tried. For the combination of anticancer drugs, the interaction of anticancer drugs is very important but unpredictable factor. In this experiments we designed and tested new experiment to measure the interaction of two anticancer drugs using MTT assay in an attempt to predict clinical response of the combination regimen. METHODS: With human lung adenocarcinoma cell line (PC-14), the cytotoxic effect of cisplatin adriamycin mitomycin C and etoposide were measured by in Vitro chemosensitivity test (MTT assay). The combined cytotexic effects of combination of two drugs were also measured in every combination of the drug concentrations and analyzed the interaction by Anova analysis of two way factorial design. RESULTS: Four individual drugs showed cytotoxic effects on PC-14 by dose dependent fashion Comparison of two drug combinations revealed that mitomycin C + cisplatin and adriamycin + cisplatin combinations showed stronger synergistic cytotoxic effects. CONCLUSION: From this experiments we suggest two combinations of mitomycin C + cisplatin and adriamycin + cisplatin as chemotherapeutic regimens for unresectable non-small cell lung cancer. Furthermore, this experimental deign could be applied b other types of cancer requiring combination anticancer chemotherapy.
